SCHEMBL2314588

SCHEMBL2314588

CCCCCCc1c2nc(c(CCCCCC)c3ccc([nH]3)c(-c3ccc(C(=O)O)cc3)c3nc(c(-c4ccc(C(=O)O)cc4)c4ccc1[nH]4)C=C3)C=C2

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TOP1 P11387 3/20 0.67
▸ CYCS P99999 3/20 0.65
▸ RARB P10826 7/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ RARA P10276 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ MTOR P42345 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ ABCG2 Q9UNQ0 1/20 0.46
▸ ENPP2 Q13822 1/20 0.43
▸ NPC1 O15118 1/20 0.42
▸ NFKB1 P19838 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ NFKB2 Q00653 1/20 0.42
▸ RELA Q04206 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ TERT O14746 1/20 0.42
▸ MPL P40238 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2314598 1.00 TOP1 (0.67) TOP1CYCSRARBMEN1ALDH1A1
SCHEMBL2310933 1.00 TOP1 (0.67) TOP1CYCSRARBMEN1ALDH1A1
SCHEMBL20843311 0.95 TOP1 (0.60) TOP1CYCSRARBMEN1ALDH1A1
SCHEMBL12451909 0.93 TOP1 (0.58) TOP1CYCSRARBMEN1ALDH1A1
SCHEMBL12392113 0.93 TOP1 (0.58) TOP1CYCSRARBMEN1ALDH1A1
SCHEMBL24689354 0.91 TOP1 (0.56) TOP1CYCSRARBMEN1ALDH1A1
SCHEMBL20843394 0.91 TOP1 (0.56) TOP1CYCSRARBMEN1ALDH1A1
SCHEMBL20843344 0.91 TOP1 (0.56) TOP1CYCSRARBMEN1ALDH1A1
SCHEMBL13459435 0.91 TOP1 (0.56) TOP1CYCSRARBMEN1ALDH1A1
SCHEMBL12392111 0.91 TOP1 (0.56) TOP1CYCSRARBMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9315510-B2 Method and application of unsymmetrically meso-substituted porphyrins and chlorins for PDT BIOLITEC PHARMA MARKETING LTD (MY) 2016-04-19 — — US claimed
EP-3459955-B1 NOVEL METHOD AND APPLICATION OF UNSYMMETRICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT BIOLITEC UNTERNEHMENSBERATUNGS II AG (AT) 2022-11-02 — — EP disclosed
EP-3459955-B1 NOVEL METHOD AND APPLICATION OF UNSYMMETRICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT BIOLITEC UNTERNEHMENSBERATUNGS II AG (AT) 2022-11-02 — — EP disclosed
EP-3459955-A1 NOVEL METHOD AND APPLICATION OF UNSYMMETRICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT biolitec Unternehmensbeteiligungs II AG (AT) 2019-03-27 — — EP disclosed
EP-3459955-A1 NOVEL METHOD AND APPLICATION OF UNSYMMETRICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT biolitec Unternehmensbeteiligungs II AG (AT) 2019-03-27 — — EP disclosed
EP-2350058-B1 NOVEL METHOD AND APPLICATION OF UNSYMMETRICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) 2018-10-24 — — EP disclosed
US-9315510-B2 Method and application of unsymmetrically meso-substituted porphyrins and chlorins for PDT BIOLITEC PHARMA MARKETING LTD (MY) 2016-04-19 — — US disclosed
US-9315510-B2 Method and application of unsymmetrically meso-substituted porphyrins and chlorins for PDT BIOLITEC PHARMA MARKETING LTD (MY) 2016-04-19 — — US disclosed
US-9315510-B2 Method and application of unsymmetrically meso-substituted porphyrins and chlorins for PDT BIOLITEC PHARMA MARKETING LTD (MY) 2016-04-19 — — US disclosed
US-20110206613-A1 METHOD AND APPLICATION OF UNSYMMETRICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) 2011-08-25 — — US disclosed
US-20110206613-A1 METHOD AND APPLICATION OF UNSYMMETRICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) 2011-08-25 — — US disclosed
US-20110206613-A1 METHOD AND APPLICATION OF UNSYMMETRICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) 2011-08-25 — — US disclosed
EP-2350058-A2 NOVEL METHOD AND APPLICATION OF UNSYMMETRICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT CeramOptec GmbH (DE) 2011-08-03 — — EP disclosed
WO-2010033678-A2 NOVEL METHOD AND APPLICATION OF UNSYMMETRICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT CERAMOPTEC INDUSTRIES, INC. (US) 2010-03-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110206613-A1 METHOD AND APPLICATION OF UNSYMMETRICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT PTDSS2, PTDSS1, DLST TOP1 3107/4885CYCS 1985/4885RARB 1107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback